
Karol Sikora, is one of the UK’s leading cancer specialists and a high-profile exponent for radical change in the NHS. …
UK-based GlaxoSmithKline has pledged a total of £235 million towards developing and selling a new cancer drug.It has teamed up …
The NHS will have to change radically and rapidly in order to meet a new government target to reduce waiting …
UK-based biotech company Protherics has raised £38 million, which will be split in a three-pronged move to expand its development …
GlaxoSmithKline Biological's mock pandemic flu vaccine has received a positive opinion from EU regulators.Daronix is intended to protect against flu …
While debate rages about many aspects of the pharmaceutical industry, one thing is agreed: our world is becoming ever-more patient-centred. …
After heavy criticism of UK medicines regulator the MHRA last year, a new survey found there is widespread confidence in …
GlaxoSmithKline's Tycerb has entered a landmark global trial in the treatment of aggressive breast cancer.This will be the first phase …
Merck's battle to regain profitability and bring new life to its product pipeline is gathering momentum as its unprecedented reorganisation …
Debt-ridden Good Hope hospital trust is set to merge with one of the country's best hospitals, the neighbouring Heart of …
The views of patients in local healthcare decision making is to be further enhanced by the creation of Local Involvement …
A controversial NHS accounting system, in which in-debt trusts are penalised with budget cuts, will continue, despite protests from health …
The UK's National Cancer Research Network has given its backing to a phase IIb trial of a promising vaccine for …
GlaxoSmithKline has bought Cambridge-based antibody firm Domantis for £230 million.Domantis, a leader in developing the next generation of antibody therapies, …
The pharmaceutical industry still refuses to fall out of love with large sales forces, but there are signs beginning to …
Oxford BioMedica's leading cancer immunotherapy vaccine has received a positive opinion as an orphan drug for renal cancer from the …
Wide-ranging changes will be made to the way clinical trials are conducted in the UK following the final report by …
Faster approval of NHS clinical trials and NICE recommendations are almost certain following a fundamental shake-up in the way UK …
Novartis will launch Prexige in its first European markets outside the UK next year following its EMEA approval for osteoarthritic …
Most UK doctors think the uptake of new medicines in the country is 'about right' according to a new survey …